This Week in Rheumatology — Jun 17, 2026

Welcome to This Week in Rheumatology. This week we're covering 8 notable papers spanning advances in precision monitoring and biomarkers, new insights into long-term risk and disease pathogenesis, and a look at novel therapeutics in related fields. Let's dive in.

Our first theme this week focuses on the move towards precision monitoring in rheumatic disease, using novel tools to predict response, track activity, and stratify risk. Two papers in Annals of the rheumatic diseases leverage advanced multiomics to provide a deeper look at the cellular dynamics of treatment. In rheumatoid arthritis, a key challenge is predicting who will respond to methotrexate, our first-line therapy. A prospective longitudinal study profiled newly diagnosed RA patients starting methotrexate and found surprisingly rapid immune changes that preceded clinical improvement [4]. As early as three weeks after starting treatment, patients who would go on to be clinical responders showed a selective decline in T follicular helper cells and plasmablasts. In contrast, these cell populations remained largely unchanged in non-responders. This finding was validated in an independent cohort, suggesting that these early cellular shifts could serve as powerful biomarkers to predict treatment response long before we would typically assess it clinically. Similarly, another deep dive in Annals of the rheumatic diseases examined patients with IgG4-related disease undergoing rituximab treatment [3]. Through a longitudinal analysis of blood and tissue, researchers identified a specific, pathogenic IgG4-positive plasma cell subset characterized by the expression of the neuropeptide NMU and a highly skewed IGHV1-69 B-cell receptor. The dynamics of this cell population, along with concurrent shifts in follicular helper T cells, mirrored disease remission and relapse. This discovery not only provides a mechanistic framework for how B-cell depletion works in IgG4-related disease, but also offers a specific cellular biomarker that could be used to monitor for disease recurrence. Beyond cellular profiling, new approaches in imaging and risk assessment are also refining how we monitor patients. In RMD Open, a proof-of-concept study explored a novel PET/CT tracer for giant cell arteritis [7]. The tracer, which targets vascular adhesion protein-1, or VAP-1, appears to specifically detect vascular inflammation. In newly diagnosed patients, tracer uptake correlated with intima-media thickness measured by vascular ultrasound and, importantly, was reduced following treatment with prednisolone. This suggests it could be a treatment-responsive molecular imaging biomarker for GCA, potentially offering more specificity than current methods. And finally, for assessing long-term risk, another study in RMD Open highlights the limitations of standard cardiovascular risk calculators in our patients [5]. In a cohort of patients with rheumatoid arthritis, systemic sclerosis, and spondyloarthritis followed for a median of 7 years, carotid-femoral pulse wave velocity—a non-invasive measure of aortic stiffness—was a strong independent predictor of future cardiovascular events. It significantly outperformed the SCORE2 risk calculator, which did not differ between patients who had an event and those who did not. This study makes a strong case for incorporating measures like pulse wave velocity for more accurate cardiovascular risk stratification in this high-risk population.

Our next theme shifts from monitoring to fundamental questions of disease risk and pathogenesis. A major study in Rheumatology challenges a common assumption about renal risk in systemic lupus erythematosus [6]. In a national database study, researchers followed over a thousand newly diagnosed SLE patients who had preserved kidney function and no evidence of lupus nephritis at baseline. Despite this seemingly low-risk profile, these patients had a nearly doubled risk of developing chronic kidney disease over a median follow-up of almost six years compared to matched controls. Their risks for end-stage kidney disease, major adverse cardiovascular events, and all-cause mortality were also significantly higher, with mortality risk being over four times greater. This is a critical finding, emphasizing that the absence of overt nephritis at diagnosis does not confer long-term renal safety in SLE. It underscores the need for vigilant, long-term monitoring of kidney function and aggressive management of modifiable risk factors like hypertension and diabetes in all SLE patients. Moving from long-term risk to core disease mechanisms, a paper in The New England journal of medicine identifies a specific autoantibody that may drive a subset of inflammatory bowel disease [2]. Researchers found that 3.5% of IBD patients had neutralizing autoantibodies against interleukin-10, a key anti-inflammatory cytokine. These autoantibodies were not found in any of the healthy controls. Their presence was associated with an exaggerated pro-inflammatory cytokine response, functionally phenocopying rare monogenic defects in IL-10 signaling. Furthermore, the presence of these autoantibodies was very strongly associated with the HLA-DRB1*01:03 allele, which is the strongest known genetic risk factor for ulcerative colitis. This work links a major genetic risk factor to a specific, pathogenic autoimmune mechanism. And broadening this concept, a review in Rheumatology reminds us to consider monogenic causes for diseases that present in adulthood [8]. The authors highlight a growing list of single-gene disorders that can mimic common rheumatologic conditions like lupus or vasculitis. These conditions often present with incomplete penetrance or atypical features, and may not follow classic inheritance patterns. The review serves as a practical guide on when to suspect a monogenic cause in an adult patient and how to approach genetic testing, emphasizing that a molecular diagnosis can refine classification and open the door to targeted, mechanism-based therapies.

Finally, we turn to therapeutics with a major trial from The New England journal of medicine in multiple myeloma, a disease with immunologic overlaps with our field [1]. The Phase 3 MonumenTAL-3 trial evaluated talquetamab, a bispecific antibody targeting GPRC5D on myeloma cells and CD3 on T cells. Patients with relapsed or refractory myeloma were randomized to receive talquetamab plus daratumumab, with or without pomalidomide, or a standard control regimen of daratumumab, pomalidomide, and dexamethasone. The results at a median follow-up of about two years were striking. Both talquetamab-containing regimens led to significantly longer progression-free survival compared to the control. The hazard ratio for disease progression or death was reduced by about 70 percent in the talquetamab groups. Response rates were also higher, with over two-thirds of patients on the talquetamab arms achieving a complete response or better, compared to about one-third in the control group. Overall survival at 24 months also favored the talquetamab combinations. While serious adverse events were slightly more frequent in the three-drug talquetamab group, fatal adverse events were actually less common than in the control arm.

If you only have time for one paper this week, make it the study from Rheumatology on the long-term risk of chronic kidney disease in SLE patients without baseline nephritis [6]. This paper's findings should directly influence the long-term surveillance strategy for a large and common patient population, reminding us that significant renal risk persists even in the absence of overt lupus nephritis at diagnosis.

Here are the key takeaways from this week in Rheumatology. First, for your SLE patients, even those with normal kidney function and no history of nephritis at diagnosis, maintain a high index of suspicion for future chronic kidney disease. This group has a nearly two-fold higher risk and warrants close long-term monitoring of renal function and aggressive management of cardiovascular risk factors [6]. Second, in assessing cardiovascular risk for patients with inflammatory arthritis or systemic sclerosis, consider carotid-femoral pulse wave velocity. A study in RMD Open found it significantly outperforms the standard SCORE2 risk calculator for predicting future cardiovascular events in this population [5]. Third, the immune response to therapy can be surprisingly rapid. New data from Annals of the rheumatic diseases shows that in RA, key changes in T-follicular helper cells and plasmablasts occur within three weeks of starting methotrexate and can predict subsequent clinical response [4]. And finally, when faced with an adult patient with an atypical or severe presentation of a seemingly common rheumatic disease, consider the possibility of an underlying monogenic disorder. A review in Rheumatology highlights that many of these conditions present in adulthood and can mimic diseases like lupus or vasculitis, and a genetic diagnosis can unlock targeted therapies [8].

That's your roundup for This Week in Rheumatology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And for audio briefings on your own clinical questions and papers, visit audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.